Cisatracurium besylate
Cisatracurium Besylate (cisatracurium besylate) is a small molecule pharmaceutical. Cisatracurium besylate was first approved as Nimbex on 1995-12-15.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nimbex (generic drugs available since 2012-02-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cisatracurium | ANDA | 2021-06-09 |
| cisatracurium besylate | ANDA | 2023-11-29 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromuscular blockade | D019148 | — | — | — | 1 | — | 4 | 4 | 9 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | 3 | — | 4 |
| General anesthesia | D000768 | — | — | — | — | — | 1 | 3 | 4 |
| Anesthesia | D000758 | — | — | — | — | — | 1 | 2 | 3 |
| Delayed emergence from anesthesia | D055191 | — | — | — | — | — | 2 | 1 | 3 |
| Postoperative complications | D011183 | — | — | — | — | — | 1 | 1 | 2 |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | — | 2 |
| Emergence delirium | D000071257 | — | — | — | — | — | 1 | 1 | 2 |
| Patient-controlled analgesia | D016058 | — | — | — | — | — | 1 | — | 1 |
| Arthroplasty | D001178 | — | — | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fasciculation | D005207 | — | R25.3 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Intraocular pressure | D007429 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 1 | 1 |
| Muscle relaxation | D009126 | — | — | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Gender identity | D005783 | — | — | — | — | — | — | 1 | 1 |
| Post-cardiac arrest syndrome | D000080942 | — | — | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | — | — | — | 1 | 1 |
| Intratracheal intubation | D007442 | — | — | — | — | — | — | 1 | 1 |
| Intra-abdominal hypertension | D059325 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cisatracurium besylate |
| INN | cisatracurium besilate |
| Description | Cisatracurium besylate is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia. It has a role as a muscle relaxant and a nicotinic antagonist. It is a quaternary ammonium salt, an atracurium besylate and an organosulfonate salt. It contains a cisatracurium. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 96946-42-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200641 |
| ChEBI ID | 3721 |
| PubChem CID | 62886 |
| DrugBank | DB00565 |
| UNII ID | 80YS8O1MBS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 519 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
985 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use